Jason Rhodes is a partner, creating and building novel therapeutics companies.

Jason is the chairman and was the founding CEO of Dyne Therapeutics (NASDAQ: DYN) and Rectify Pharmaceuticals and was the chairman and founding CEO of Disarm Therapeutics, developing a novel SARM1 inhibitor for patients with ALS, acquired by Eli Lilly. He is also the chairman of Accent Therapeutics, K36 Therapeutics, and KaryoVerse and on the boards of AAVantgarde Bio, Mithril, and Weaver.

Previously, Jason held leadership positions at Alnylam Pharmaceuticals (NASDAQ: ALNY) and Epizyme (NASDAQ: EPZM), where he built the company from early-stage research into the clinic and through a successful IPO. Jason was also a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including FoldRx, the developer of tafamadis, acquired by Pfizer.

Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.

Jason serves on the Advisory Board of the Vagelos Program in Life Sciences and Management at the University of Pennsylvania and on the Board of Trustees of the American Academy in Rome. He spends his free time mountain biking and loudly watching Spanish fútbol with his family.